INCY
Incyte
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 2
ample liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About INCY
Incyte Corporation
A global biopharmaceutical company that develops small molecule drugs to treat cancer and inflammatory diseases
Biological Technology
Invalid Date
11/04/1993
NASDAQ Stock Exchange
2617
12-31
Common stock
1801 Augustine Cut-Off, Wilmington, DE 19803
--
Incyte Corporation was incorporated in Delaware in 1991. The Company is a global biopharmaceutical company dedicated to the discovery, development and commercialization of proprietary therapies. The company focuses on two therapeutic areas defined by the indications of its approved drugs and the diseases in development of its clinical candidates. One therapeutic area is hematology/oncology, including myeloproliferative tumors (MPN), graft-versus-host disease (GVHD), solid tumors and hematological malignancies. Another therapeutic area is inflammation and autoimmunity (IAI), including its dermatology commercial franchise. The company is also entitled to milestones and royalties on molecules it discovers and licenses to third parties.
Earnings Call
Friday, May 9 03:40
2025-Q1
Estimate EPS1.05
Actual EPS1.16
Estimate Revenue996.57M
Actual Revenue1.05B
Incyte's Q1 2025 Earnings Call: Unraveling Contradictions in Jakafi Growth, Pipeline Strategy, and Capital Allocation
05/09/2025·Earnings Decrypt
Company Financials
EPS
INCY has released its 2025 Q1 earnings. EPS was reported at 1.16, versus the expected 1.05, beating expectations. The chart below visualizes how INCY has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
INCY has released its 2025 Q1 earnings report, with revenue of 1.05B, reflecting a YoY change of 19.53%, and net profit of 158.20M, showing a YoY change of -6.69%. The Sankey diagram below clearly presents INCY’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
